Physician profile
Maher Tama
NPI 1326393737
$1,230.50
in general payments reported to CMS, 2019-2025
16 companies · $19.77 in 2025
The $19.77 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $76.83 · 2021: $246 · 2022: $351 · 2024: $34.57 · 2025: $19.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.70 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $129.50 | 2022-2024 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $110.99 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $67.50 | 2019 | |
| Covidien Lp | $65.00 | 2019 | |
| Gilead Sciences, INC. | $53.47 | 2019 | |
| Glaukos Corporation | $31.82 | 2022 | |
| Janssen Biotech, INC. | $27.57 | 2019 | |
| Nestle Healthcare Nutrition INC. | $21.07 | 2020 | |
| Alexion Pharmaceuticals, INC. | $21.04 | 2019 | |
| Olympus America INC. | $19.77 | 2025 | Visiglide |
| Pfizer INC. | $17.06 | 2019 | |
| Intercept Pharmaceuticals, INC. | $15.71 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Tama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.